GSK Plc - ADR

GSK Plc - ADR

GSK

Get informed when a big investor buys or sells

+ Follow
Market Cap$106.11B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
GSK Plc - ADRGSK Plc - ADR16.33.42%87%0.31

Earnings Call Q2 2026

July 28, 2026 - AI Summary

Q2 performance: strong earnings momentum (with infrastructure leading) - Infrastructure adjusted EBITDA: CAD 169m, a CAD +17m YoY increase vs Q2’25 and CAD +9m above the prior quarterly record (Q4’25). - Drivers: stronger network utilization, Chauvin contribution, and optimization initiatives (about +8m barrels throughput vs Q2’25). - Marketing adjusted EBITDA: CAD 15m in Q2 (vs CAD 8m in Q2’25) — described as the strongest marketing quarter since Q2’24, benefiting from strong refined product crack spreads and improved Moose Jaw product mix. - Consolidated adjusted EBITDA: CAD 169m (in line with the prior quarterly record) and CAD +22m YoY. - Distributable cash flow: CAD 96m (+CAD 15m YoY), partially offset by higher financing costs and current income taxes.
Outlook / guidance: marketing seasonality + near-term operational assumptions - Management expects Q3 marketing to remain strong, tied to continued strength in refined product cracks and supportive mix. - They reiterated marketing is expected to fall within the “0 to CAD 40m” annual guidance range, and performance in Q2 was better than anticipated, trending toward the upper end of CAD 40m (year-to-date marketing: CAD 18m). - Seasonality risk: Q4 is expected to reflect refined-products seasonality (i.e., less upside vs Q3). - Exports/ship availability volatility: company expects Q3 volume to be similar to Q2 on a contractual/locked-in basis, but actual volumes depend on tanker/vessel availability and loading—described as changing daily.
Growth strategy: key capex/projects progressing + acquisition integration - Chauvin Pipeline acquisition closed May 1: adds stable contracted cash flows supported by long-term agreements (with TGE). - Hardisty connection project: started post-close; directly connects Chauvin assets to the core Hardisty terminal; expected completion in 1H’27. - Chauvin expansion (capacity +50%): engineering underway to increase effective capacity from 30,000 bpd to 45,000 bpd; on track for FID by year-end. - U.S. Wink-to-Gateway integration: on track to be placed into service by end of Q3; initial pipeline twinning work is complete to improve concurrent supply into Gateway. - Investor day growth posture remains intact: projects aim to support sustainable long-term value and per-share growth (team is targeting a CAD 1B growth capital deployment over ~5 years).

Exclusive for Stockcircle Pro members

Sign upSign Up
$107.85

Current Fair Value

113.8% upside

Undervalued by 113.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$106.11 Billion
Enterprise Value$121.15 Billion
Dividend Yield$1.80 (3.42%)
Earnings per Share$2.82
Beta0.3
Outstanding Shares2,007,000,000

Return

Return on Equity86.80%ROE
Return on Assets24.81%
Return on Invested Capital46.40%

Valuation & Multiples

P/E Ratio16.34P/E Ratio
PEG-23.44PEG
Price to Sales0.34Price to Sales
Price to Book Ratio6.31Price to Book Ratio
Enterprise Value to Revenue0.41
Enterprise Value to EBIT6.53
Enterprise Value to Net Income7
Total Debt to Enterprise0.15
Debt to Equity1.03Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 29, 2026
EPS Estimate
$1.27
Average shareholder expectation
Revenue Estimate
$11.04 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 28, 2026
EPS Estimate
$1.37
Average shareholder expectation
Revenue Estimate
$11.88 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio7.0678 651.57%
Total Calls101,700 96.89%
Total Puts718,800 60.24%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %4.27% 14.35%
Total Invested$4.49B 78.26%
Investors Holding631 427.00%

ESG Score

No data

About Glaxosmithkline plc

CEO: Emma Walmsley